ANI Pharma Inc (ANIP) Stock Price, Quote & News

Company Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chain...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 218 634 3500

Fax: 218 634 3540

Website: www.anipharmaceuticals.com

Address:

210 Main Street West, Baudette, United States

WestEgg Dec. 5 at 8:26 PM

$ANIP house of cards about to fall

0 · Reply

ZacksResearch Nov. 28 at 4:02 PM

$ANIP vs. $AMRX — one of these niche drugmakers is shaping up as the clear momentum play. ANI Pharmaceuticals is riding rare-disease strength, with surging Cortrophin Gel sales giving it the stronger growth profile compared to its more diversified rival. Full breakdown here 👉 https://www.zacks.com/stock/news/2797189/anip-vs-amrx-which-niche-drugmaker-is-the-better-pick?cid=sm-stocktwits-2-2797189-teaser-22735&ADID=SYND_STOCKTWITS_TWEET_2_2797189_TEASER_22735

0 · Reply

ZacksResearch Nov. 28 at 3:02 PM

$ANIP vs. $AMRX: Which stock has the edge? 🏆 ANIP's rare disease sales are booming, with Cortrophin Gel sales expected to soar 75-78% over the prior year for 2025 📈. Meanwhile, AMRX faces margin pressures despite its diversified model 🤔. Discover why ANIP holds the advantage right now 👉 https://www.zacks.com/stock/news/2797189/anip-vs-amrx-which-niche-drugmaker-is-the-better-pick?cid=sm-stocktwits-2-2797189-body-22729&ADID=SYND_STOCKTWITS_TWEET_2_2797189_BODY_22729

0 · Reply

ZacksResearch Nov. 21 at 2:16 PM

$ANIP's rare disease franchise is on fire in 2025! 🔥 💊 Revenues more than doubled YoY to $291M in the first nine months 📈 Cortrophin Gel sales expected to reach $347-$352M, reflecting a 75-78% increase from last year 📉 Ophthalmology assets face reimbursement challenges with sales revised to $73-$77M, but recovery expected in 2026 Discover why ANIP's a Zacks Rank #1 (Strong Buy) 👉 https://www.zacks.com/stock/news/2794097/heres-how-anips-rare-disease-portfolio-is-driving-top-line-growth?cid=sm-stocktwits-2-2794097-body-21991&ADID=SYND_STOCKTWITS_TWEET_2_2794097_BODY_21991

0 · Reply

ZacksResearch Nov. 21 at 1:16 PM

$ANIP is quietly turning its rare disease lineup into a real growth engine. Top-line momentum is being driven straight from that rare disease portfolio — and that’s exactly where the market loves to see durable strength. Full breakdown here 👉 https://www.zacks.com/stock/news/2794097/heres-how-anips-rare-disease-portfolio-is-driving-top-line-growth?cid=sm-stocktwits-2-2794097-teaser-21989&ADID=SYND_STOCKTWITS_TWEET_2_2794097_TEASER_21989

0 · Reply

merlin8121 Nov. 20 at 8:35 PM

$ANIP https://www.merlintrader.com/top-10-healthcare-small-caps-stocks/

0 · Reply

CunningStunt69 Nov. 20 at 3:38 PM

$ANIP had to jump out of this at $93 to chase another stock. Glad I got the chance to get back in.

0 · Reply

BEATOFtheMARKET Nov. 16 at 10:39 PM

$ANET $ANF $ANIP $AON $APD

0 · Reply

ZacksResearch Nov. 14 at 1:44 PM

ANIP is ripping 53% YTD — but is this run just getting started or running hot? $ANIP is riding strong 2025 financial performance, a raised outlook, and serious momentum in its rare disease portfolio. That’s the kind of trifecta that keeps buyers coming back. Opportunity breakdown here 👉 https://www.zacks.com/stock/news/2791143/ani-pharmaceuticals-stock-surges-53-ytd-time-to-buy-or-sell?cid=sm-stocktwits-2-2791143-teaser-21105&ADID=SYND_STOCKTWITS_TWEET_2_2791143_TEASER_21105

0 · Reply

ZacksResearch Nov. 14 at 12:44 PM

$ANIP: 53% YTD surge — can it keep climbing? 🚀 💊 Rare disease sales more than doubled in the first nine months of 2025 to $291M, with Cortrophin Gel driving the momentum. 📈 Raised FY25 guidance now implies 39-42% annual sales growth — a bullish signal. 🔍 Despite competition, generics still projected for low-20% growth. See why ANIP might still be a buy here 👉 https://www.zacks.com/stock/news/2791143/ani-pharmaceuticals-stock-surges-53-ytd-time-to-buy-or-sell?cid=sm-stocktwits-2-2791143-body-21103&ADID=SYND_STOCKTWITS_TWEET_2_2791143_BODY_21103

0 · Reply

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise

Dec 1, 2025, 6:50 AM EST - 5 days ago

ANI Pharmaceuticals Announces Board Transition

Nov 25, 2025, 6:50 AM EST - 11 days ago

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 11, 2025, 4:05 PM EST - 25 days ago

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London

Nov 7, 2025, 2:16 PM EST - 4 weeks ago

ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 6:50 AM EST - 4 weeks ago

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

Oct 28, 2025, 5:54 PM EDT - 5 weeks ago

ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates

Oct 24, 2025, 6:50 AM EDT - 6 weeks ago

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

Oct 16, 2025, 6:50 AM EDT - 7 weeks ago

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

Sep 9, 2025, 4:41 PM EDT - 3 months ago

ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 4:30 PM EDT - 3 months ago

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

Aug 8, 2025, 3:56 PM EDT - 4 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 6:50 AM EDT - 4 months ago

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

Aug 1, 2025, 6:50 AM EDT - 4 months ago

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

Jul 23, 2025, 6:50 AM EDT - 4 months ago

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

Jul 2, 2025, 6:50 AM EDT - 5 months ago

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

Jun 12, 2025, 7:00 AM EDT - 6 months ago

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

May 27, 2025, 4:30 PM EDT - 6 months ago

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 27, 2025, 7:20 AM EDT - 6 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

AGL OMER

May 22, 2025, 6:50 AM EDT - 7 months ago

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

May 12, 2025, 6:30 PM EDT - 7 months ago

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

May 9, 2025, 11:44 AM EDT - 7 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

May 9, 2025, 6:50 AM EDT - 7 months ago

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

May 6, 2025, 5:43 AM EDT - 7 months ago

ANI Pharmaceuticals: A Short-Term Buying Opportunity

May 5, 2025, 7:00 AM EDT - 7 months ago

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

Apr 9, 2025, 6:50 AM EDT - 8 months ago

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

Mar 31, 2025, 4:30 PM EDT - 8 months ago

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 19, 2025, 6:50 AM EDT - 9 months ago

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

Mar 18, 2025, 6:50 AM EDT - 9 months ago

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

Mar 14, 2025, 6:50 AM EDT - 9 months ago

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

Mar 3, 2025, 4:30 PM EST - 9 months ago

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

Feb 28, 2025, 5:45 PM EST - 10 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 10:37 AM EST - 10 months ago

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

Feb 28, 2025, 6:50 AM EST - 10 months ago

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

Feb 19, 2025, 4:30 PM EST - 10 months ago

ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

Feb 18, 2025, 4:05 PM EST - 10 months ago

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

Feb 11, 2025, 9:08 AM EST - 10 months ago

ANI Pharmaceuticals: More Than Just A Generics Company

Jan 28, 2025, 4:30 PM EST - 11 months ago

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

Jan 13, 2025, 11:12 AM EST - 11 months ago

Alcami Announces CEO Transition

Jan 13, 2025, 6:50 AM EST - 11 months ago

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

Jan 2, 2025, 6:50 AM EST - 1 year ago

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

Dec 30, 2024, 4:05 PM EST - 1 year ago

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 1 year ago

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 11:05 PM EST - 1 year ago

ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 6:50 AM EST - 1 year ago

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

Nov 4, 2024, 4:30 PM EST - 1 year ago

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

Oct 30, 2024, 5:00 PM EDT - 1 year ago

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET

Oct 25, 2024, 6:50 AM EDT - 1 year ago

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

Oct 24, 2024, 6:50 AM EDT - 1 year ago

ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024

Oct 11, 2024, 1:40 PM EDT - 1 year ago

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential

WestEgg Dec. 5 at 8:26 PM

$ANIP house of cards about to fall

0 · Reply

ZacksResearch Nov. 28 at 4:02 PM

0 · Reply

ZacksResearch Nov. 28 at 3:02 PM

0 · Reply

ZacksResearch Nov. 21 at 2:16 PM

0 · Reply

ZacksResearch Nov. 21 at 1:16 PM

0 · Reply

merlin8121 Nov. 20 at 8:35 PM

$ANIP https://www.merlintrader.com/top-10-healthcare-small-caps-stocks/

0 · Reply

CunningStunt69 Nov. 20 at 3:38 PM

$ANIP had to jump out of this at $93 to chase another stock. Glad I got the chance to get back in.

0 · Reply

BEATOFtheMARKET Nov. 16 at 10:39 PM

$ANET $ANF $ANIP $AON $APD

0 · Reply

ZacksResearch Nov. 14 at 1:44 PM

0 · Reply

ZacksResearch Nov. 14 at 12:44 PM

0 · Reply

SuperGreenToday Nov. 14 at 1:11 AM

$ANIP Share Price: $84.29 Contract Selected: Apr 17, 2026 $85 Calls Buy Zone: $6.12 – $7.56 Target Zone: $10.77 – $13.16 Potential Upside: 66% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BEATOFtheMARKET Nov. 11 at 5:44 PM

$ANET $ANF $ANIP $AON $APD 🔥

0 · Reply

JarvisFlow Nov. 10 at 2:47 PM

Guggenheim updates rating for ANI Pharmaceuticals ( $ANIP ) to Buy, target set at 114 → 115.

0 · Reply

DonCorleone77 Nov. 10 at 1:29 PM

$ANIP ENORMOUS price target upgrade 😉 Guggenheim raises price target on ANI Pharmaceuticals to $115 from $114 -- Keeps 'Buy' rating.

0 · Reply

BEATOFtheMARKET Nov. 9 at 9:19 PM

$AMZU $AN $ANET $ANIP $AON

0 · Reply

DonCorleone77 Nov. 7 at 11:59 AM

$ANIP ANI Pharmaceuticals reports Q3 adjusted EPS $2.04, consensus $1.77 -- Q3 revenue $227.8M, consensus $212.85M. -- Raises FY25 adj. EPS view to $7.37-$7.64 from $6.98-$7.35, cconsensus $7.32. -- Raises FY25 revenue view to $854M-$873M from $818M-$834M, consensus $847.99M. -- Raises FY25 adjusted EBITDA view to $221M-$228M from $213M-$223M.

0 · Reply

ZacksResearch Nov. 6 at 3:54 PM

$RXRX plunges 26.7% YTD — is the biotech sector leaving it behind? Despite a narrower-than-expected Q3 loss, revenue fell short of estimates, though the company's strategic pipeline shifts focus on more promising candidates. Meanwhile, other biotech stocks like $ANIP (Rank #2) and $ACAD (Rank #2) are showing stronger Zacks Ranks and earnings momentum. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2786757/rxrx-q3-loss-narrower-than-expected-revenues-decline-yy?cid=sm-stocktwits-2-2786757-body-19838&ADID=SYND_STOCKTWITS_TWEET_2_2786757_BODY_19838

0 · Reply

BEATOFtheMARKET Nov. 4 at 8:53 PM

$AON $ANIP $ANET $AN $AMZU 🔥

0 · Reply

ZacksResearch Nov. 3 at 2:33 PM

4 biotech stocks primed for a surprise — are you ready? 🔍 💊 $ZYME: +2.22% Earnings ESP, Zacks Rank #1, reporting Nov. 6 🧬 $NKTR: +18.72% Earnings ESP, Zacks Rank #2, reporting Nov. 6 💉 $ANIP: +10.55% Earnings ESP, Zacks Rank #2, reporting Nov. 7 🔬 $PCRX: +2.68% Earnings ESP, Zacks Rank #3, reporting Nov. 6 Discover their potential for earnings surprises here 👉 https://www.zacks.com/stock/news/2783287/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates?cid=sm-stocktwits-2-2783287-body-19028&ADID=SYND_STOCKTWITS_TWEET_2_2783287_BODY_19028

1 · Reply

ZacksResearch Nov. 3 at 1:33 PM

Biotech breakout ahead? 🔬 $ZYME, $NKTR, $ANIP, and $PCRX are all positioned for potential Q3 earnings surprises, with sector momentum pointing to upside. Full earnings preview here 👉 https://www.zacks.com/stock/news/2783287/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates?cid=sm-stocktwits-2-2783287-teaser-19027&ADID=SYND_STOCKTWITS_TWEET_2_2783287_TEASER_19027

0 · Reply

Doozio Oct. 28 at 1:30 AM

$ANIP another gap n go on eps? Only da 🐑 will be shook 🐒🍌🧠⏰♾️

0 · Reply

ZacksResearch Oct. 27 at 5:53 PM

Could $ANIP be gearing up for another earnings beat? 👀 Rising Cortrophin Gel sales and momentum from new rare disease products — plus strength in generics — could set the stage for another strong Q3. Find out if ANIP’s setup points to upside this quarter 👉 https://www.zacks.com/stock/news/2778134/ani-pharmaceuticals-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2778134-teaser-17873&ADID=SYND_STOCKTWITS_TWEET_2_2778134_TEASER_17873

0 · Reply

Market Cap	1.84B
Revenue (ttm)	614.38M
Net Income (ttm)	-18.52M
EPS (ttm)	N/A
PE Ratio	14.41
Forward PE	13.48
Profit Margin	-3.01%
Debt to Equity Ratio	0.62

Volume	519,600
Avg Vol	385,690
Day's Range	N/A - N/A
Shares Out	22.47M
Stochastic %K	49%
Beta	0.48
Analysts	Strong Sell
Price Target	$109.88